secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2026-03-23T23:59:59+00:00
Accession:  0001193125-26-118544
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio announces Q4 net income $10.4M, cash $137.5M, runway through 2027
-----------------------------------------------------------------------

- Net income of $10.4M in Q4 2025 vs net loss of $13.1M in Q4 2024; full year net loss narrowed to $35.0M from $58.2M.
- Cash and cash equivalents $137.5M at Dec 31, 2025, up from $55.3M end of 2024; cash runway extended through end of 2027.
- XTX501 (bispecific PD-1/masked IL-2) on track for IND submission mid-2026 and Phase 1 start H2 2026; initial data expected H2 2027.
- Advancing masked T cell engagers: CLDN18.2 program preclinical data at AACR April 2026; PSMA/STEAP1 candidate nomination Q2 2026.
- Recent capital raises: $35.8M from Series B warrant exercises (Jan 2026) and $40.0M follow-on offering (Feb 2026).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526118544/0001193125-26-118544-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526118544/xlo-20260323.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-118544

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer